Información de Novavax Inc, dividendo de Novavax Inc, actividades de los accionistas y más

Más Datos de Novavax Inc Compañía

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.

Información de Novavax Inc



Símbolo de cotizaciónNVAX

Nombre de la empresaNovavax Inc

Fecha de salida a bolsaMay 16, 1973

Director ejecutivoJacobs (John C)

Número de empleados952

Tipo de seguridadOrdinary Share

Fin del año fiscalMay 16

Dirección21 Firstfield Rd

CiudadGAITHERSBURG

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal20878

Teléfono12402682000

Sitio Webhttps://www.novavax.com/?locale=US

Símbolo de cotizaciónNVAX

Fecha de salida a bolsaMay 16, 1973

Director ejecutivoJacobs (John C)

Ejecutivos de Novavax Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. John C. Jacobs

President, Chief Executive Officer, Director

306.56K

--

Ms. Elaine O'hara

Executive Vice President, Chief Strategy Officer

134.64K

--

Mr. Mark J. Casey

Executive Vice President, Chief Legal Officer, Company Secretary

90.07K

--

Mr. David M. (Dave) Mott

Independent Director

79.77K

+10.61%

Dr. Richard H. Douglas, Ph.D.

Independent Director

73.22K

+11.55%

Mr. Richard J. (Rick) Rodgers

Independent Director

47.37K

+17.86%

Ms. Rachel K. King

Independent Director

44.07K

+19.20%

Dr. Ruxandra Draghia-Akli, M.D., Ph.D.

Executive Vice President, Head of Research & Development

23.56K

--

Mr. Gregg Huber Alton, J.D.

Independent Director

--

Ms. Margaret G. (Margie) Mcglynn

Independent Chairman of the Board

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. John C. Jacobs

President, Chief Executive Officer, Director

306.56K

--

Ms. Elaine O'hara

Executive Vice President, Chief Strategy Officer

134.64K

--

Mr. Mark J. Casey

Executive Vice President, Chief Legal Officer, Company Secretary

90.07K

--

Mr. David M. (Dave) Mott

Independent Director

79.77K

+10.61%

Dr. Richard H. Douglas, Ph.D.

Independent Director

73.22K

+11.55%

Mr. Richard J. (Rick) Rodgers

Independent Director

47.37K

+17.86%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

Por negocioUSD

Nombre

Ganancia

Proporción

Product

685.04M

60.97%

Licensing Royalties And Other

438.44M

39.03%

Grant

0.00

0.00%

Por regiónUSD

Nombre

Ganancia

Proporción

Canada

575.67M

51.24%

United States

405.61M

36.10%

Rest of the world

126.46M

11.26%

Europe

15.74M

1.40%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Product

685.04M

60.97%

Licensing Royalties And Other

438.44M

39.03%

Grant

0.00

0.00%

Estadísticas de accionistas

Actualizado: lun., 2 de mar

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.30%

Shah Capital Management, Inc.

8.95%

BlackRock Institutional Trust Company, N.A.

6.89%

State Street Investment Management (US)

5.79%

Sanofi SA

4.18%

Otro

64.88%

Accionistas

Proporción

The Vanguard Group, Inc.

9.30%

Shah Capital Management, Inc.

8.95%

BlackRock Institutional Trust Company, N.A.

6.89%

State Street Investment Management (US)

5.79%

Sanofi SA

4.18%

Otro

64.88%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

25.77%

Investment Advisor/Hedge Fund

24.87%

Hedge Fund

8.40%

Research Firm

8.32%

Corporation

4.18%

Individual Investor

0.82%

Pension Fund

0.51%

Bank and Trust

0.50%

Insurance Company

0.03%

Otro

26.60%

Participación institucional



Actualizado: mié., 1 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

557

128.09M

77.98%

+7.28M

2025Q4

548

103.32M

63.58%

-4.81M

2025Q3

546

95.10M

58.55%

-6.89M

2025Q2

553

108.80M

66.99%

-11.74M

2025Q1

575

113.82M

70.29%

-16.33M

2024Q4

593

111.51M

69.72%

-5.93M

2024Q3

597

103.31M

64.96%

-4.25M

2024Q2

652

92.80M

65.79%

-10.97M

2024Q1

753

86.51M

64.06%

-11.91M

2023Q4

848

86.68M

74.23%

+6.21M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

15.44M

9.47%

+275.80K

+1.82%

Dec 31, 2025

Shah Capital Management, Inc.

14.56M

8.94%

+1.17M

+8.71%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

11.34M

6.96%

+124.79K

+1.11%

Dec 31, 2025

State Street Investment Management (US)

9.52M

5.84%

+2.33M

+32.33%

Dec 31, 2025

Sanofi SA

6.88M

4.22%

--

Dec 31, 2025

BofA Global Research (US)

8.29M

5.09%

+5.19M

+167.35%

Dec 31, 2025

D. E. Shaw & Co., L.P.

5.99M

3.68%

+1.72M

+40.21%

Dec 31, 2025

Millennium Management LLC

4.47M

2.74%

+2.34M

+110.13%

Dec 31, 2025

UBS Financial Services, Inc.

4.80M

2.94%

+1.47M

+44.28%

Dec 31, 2025

Geode Capital Management, L.L.C.

3.72M

2.28%

-70.74K

-1.87%

Dec 31, 2025

ETFs relacionados



Actualizado: mar., 2 de dic

Nombre

Proporción

ProShares Nanotechnology ETF

2.78%

iShares Genomics Immunology and Healthcare ETF

2.63%

Virtus LifeSci Biotech Products ETF

1.88%

ALPS Medical Breakthroughs ETF

0.55%

State Street SPDR S&P Biotech ETF

0.53%

First Trust Small Cap Value AlphaDEX Fund

0.51%

Direxion Daily S&P Biotech Bull 3X Shares

0.33%

First Trust Small Cap Core Alphadex Fund

0.19%

ProShares Ultra Nasdaq Biotechnology

0.13%

Invesco Nasdaq Biotechnology ETF

0.13%

ProShares Nanotechnology ETF

Proporción2.78%

iShares Genomics Immunology and Healthcare ETF

Proporción2.63%

Virtus LifeSci Biotech Products ETF

Proporción1.88%

ALPS Medical Breakthroughs ETF

Proporción0.55%

State Street SPDR S&P Biotech ETF

Proporción0.53%

First Trust Small Cap Value AlphaDEX Fund

Proporción0.51%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.33%

First Trust Small Cap Core Alphadex Fund

Proporción0.19%

ProShares Ultra Nasdaq Biotechnology

Proporción0.13%

Invesco Nasdaq Biotechnology ETF

Proporción0.13%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos